Optical Imaging of Matrix Metalloproteinase–2 Activity in Tumors: Feasibility Study in a Mouse Model
Top Cited Papers
- 1 November 2001
- journal article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 221 (2) , 523-529
- https://doi.org/10.1148/radiol.2212010368
Abstract
PURPOSE: To develop an optical imaging method to determine the expression level of tumoral matrix metalloproteinase–2 (MMP-2) in vivo. MATERIALS AND METHODS: An optical contrast agent was developed that was highly activatable by means of MMP-2–induced conversion. Signal characteristics of the probe were quantified ex vivo with a recombinant enzyme. Animal tumor models were established with MMP-2–positive (human fibrosarcoma cell line, n = 4) and MMP-2–negative (well-differentiated mammary adenocarcinoma, n = 4) tumor cell lines. Both tumors were implanted into nude mice and were optically imaged after intravenous administration of the MMP-2–sensitive probe. RESULTS: The MMP-2–sensitive probe was activated by MMP-2 in vitro, producing up to an 850% increase in near-infrared fluorescent signal intensity. This activation could be blocked by MMP-2 inhibitors. MMP-2–positive tumors were easily identified as high-signal-intensity regions as early as 1 hour after intravenous injection of the MMP-2 probe, while c...Keywords
This publication has 34 references indexed in Scilit:
- MMP-2 and TIMP-2 Expression Correlates with Poor Prognosis in Cervical Carcinoma—A Clinicopathologic Study Using Immunohistochemistry and mRNA in Situ HybridizationGynecologic Oncology, 1999
- Increase in Interphotoreceptor Matrix Gelatinase A (MMP-2) Associated with Age-related Macular DegenerationExperimental Eye Research, 1998
- Near‐Infrared Images Using Continuous, Phase‐Modulated, and Pulsed Light with Quantitation of Blood and Blood OxygenationaAnnals of the New York Academy of Sciences, 1998
- Cytokines secreted by glial cells infected with HTLV-I modulate the expression of matrix metalloproteinases (MMPs) and their natural inhibitor (TIMPs): possible involvement in neurodegenerative processesMolecular Psychiatry, 1997
- A Long-Circulating co-Polymer in “Passive Targeting” to Solid TumorsJournal of Drug Targeting, 1997
- Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancerEuropean Journal Of Cancer, 1996
- Hypothalamic growth hormone-releasing hormone mRNA varies across the day in ratsNeuroReport, 1996
- Suicidal tumor proteasesNature Biotechnology, 1996
- Matrix Metalloproteinases and Cardiovascular DiseaseCirculation Research, 1995
- A matrix metalloproteinase expressed on the surface of invasive tumour cellsNature, 1994